Key genetic differences found in people with chronic fatigue syndrome

Research conducted on genetic factors associated with chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) has revealed significant findings from a comprehensive study. By analyzing DNA samples from over 15,000 individuals diagnosed with CFS, scientists have identified eight regions within the human genome that may contribute to the development of this debilitating condition.

Sonya Chowdhury, from the UK charity Action for ME, acknowledges the groundbreaking nature of these findings, stating that it provides concrete evidence of the genetic underpinnings of ME. The implications of this research extend to the potential development of novel diagnostic tools and treatment strategies for individuals suffering from ME/CFS, a condition characterized by severe post-exertional malaise.

Individuals with ME/CFS have often faced skepticism and disbelief regarding the legitimacy of their illness. The identification of genetic factors lends credibility to their experiences and challenges the misconceptions surrounding the condition. Andy Devereux-Cooke, a long-term ME/CFS patient and co-founder of the Science for ME forum, emphasizes the significance of this research in validating the experiences of individuals living with ME.

The study, known as DecodeME, involved a comparison of DNA samples from a cohort of 15,500 ME/CFS patients and 260,000 control subjects without the condition, all of European descent in the UK. The analysis revealed eight distinct genetic signals associated with ME/CFS, indicating a potential genetic predisposition to the illness. These genetic regions contain 43 protein-coding genes, with a particular focus on genes related to the immune and nervous systems, predominantly active in brain tissues.

One of the identified genes, RABGAP1L, linked to immune system function, aligns with the common experience of ME/CFS patients reporting an initial infection preceding the onset of symptoms. Jackie Cliff from Brunel University of London commends the study for advancing our understanding of the immune system’s role in ME/CFS pathophysiology.

Despite the higher prevalence of ME/CFS in women, the study did not find any gender-specific differences in genetic risk. Further investigations into the X and Y sex chromosomes remain pending. The next phase of research aims to delve deeper into the identified genome regions to elucidate the molecular mechanisms driving ME/CFS and potentially pave the way for targeted therapies.

The socio-economic impact of ME/CFS is substantial, affecting an estimated 67 million individuals globally and costing the UK economy billions annually. Chris Ponting from the University of Edinburgh underscores the urgent need for increased funding and attention towards ME/CFS research to address the challenges faced by individuals living with this overlooked condition.